Oxcarbazepine, sold under the brand name Trileptal among others, is a medication used to treat epilepsy. For epilepsy it is used for both focal seizures and generalized seizures. It has been used both alone and as add-on therapy in people with bipolar disorder who have had no success with other treatments. It is taken by mouth.Common side effects include nausea, vomiting, dizziness, drowsiness, double vision and trouble with walking. Serious side effects may include anaphylaxis, liver problems, pancreatitis, suicide ideation, and an abnormal heart beat. While use during pregnancy may harm the baby, use may be less risky than having a seizure. Use is not recommended during breastfeeding. In those with an allergy to carbamazepine there is a 25% risk of problems with oxcarbazepine. How it works is not entirely clear.Oxcarbazepine was patented in 1969 and came into medical use in 1990. It is available as a generic medication. In 2019, it was the 162nd most commonly prescribed medication in the United States, with more than 3 million prescriptions. Medical uses
Oxcarbazepine is an anticonvulsant used to reduce the occurrence of epileptic episodes, and is not intended to cure epilepsy. Oxcarbazepine is used alone or in combination with other medications for the treatment of focal (partial) seizures in adults. In pediatric populations, it can be used by itself for the treatment of partial seizures for children 4 years and older, or in combination with other medications for children 2 years and older.
Auditory neuropathy spectrum disorder (ANSD) is a specific form of hearing loss defined by the presence of normal or near-normal otoacoustic emissions (OAEs) but the absence of normal middle ear reflexes and severely abnormal or completely absent auditory brainstem response (ABRs). Individuals presenting with this recently recognised hearing loss appear to display sporadic windows of hearing and not. Very few (1 in 14) will go on to develop normal speech and language but with poor speech perception in background noise and in others, no speech perception and therefore language development is possible. The condition was originally termed auditory neuropathy (AN)  and in 2001 as Auditory Neuropathy / Auditory Dys-synchrony (AN/AD)  (to include those cases where no true neuropathy was apparent). In 2008 at a meeting convened at Lake Como in Italy (Guidelines Development
Conference on the Identification and Management
of Infants with Auditory Neuropathy, International
Newborn Hearing Screening Conference, Como, Italy,
June 19–21, 2008), a group of leading authorities on the condition reached a consensus and renamed it as auditory neuropathy spectrum disorder. See also
Audiologist
Auditory brainstem response
Auditory neuropathy
Auditory processing disorder
Cochlear implant
Hearing aids
Otoacoustic emissions
Sensorineural hearing impairment

References
External links
Alices Story - A Blog Dedicated to a Beautiful Little Girl Who Has Ears That Need New Batteries